{"ModuleTitle": "Company Description", "CompanyName": "Chimerix, Inc.", "Symbol": "CMRX", "Address": "2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, North Carolina, 27713, United States of America", "Phone": "919.806.1074", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Chimerix is a development-stage biopharmaceutical company dedicated to\r\naccelerating the advancement of innovative medicines that make a meaningful\r\nimpact in the lives of patients living with cancer and other serious diseases.\r\nOur two clinical-stage development programs are dociparstat sodium (DSTAT) and\r\nbrincidofovir (BCV).\r\n\r\n\r\n                                       3\r\n\r\n--------------------------------------------------------------------------------\r\n\r\n\r\nDociparstat sodium (DSTAT)\r\n\r\nIn July 2019, we entered into a Development and License Agreement, or the\r\nLicense Agreement, with Cantex Pharmaceuticals (Cantex), pursuant to which we\r\nacquired exclusive worldwide rights to develop and commercialize DSTAT for all\r\nindications; the planned lead indication is for the first line treatment of\r\nacute myeloid leukemia (AML) in combination with cytotoxic chemotherapy.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f25%2f0001117480-20-000006.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Allen Melemed", "title": "Chief Medical Officer"}, {"name": "Michael A. Sherman", "title": "President, Chief Executive Officer & Director"}, {"name": "Michael T. Andriole", "title": "Chief Financial & Business Officer"}, {"name": "Randall Lanier", "title": "Chief Scientific Officer"}, {"name": "Roy W. Ware", "title": "Chief Technology & Manufacturing Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}